Atlas Trials

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Clinical trial NCT04348045 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04348045
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Adenocarcinoma
Start date
2020-12-07
Primary completion
2023-06-15
Enrollment
307

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.